Company Filing History:
Years Active: 2019
Title: The Innovations of Christian René Schnell
Introduction
Christian René Schnell is an accomplished inventor based in Hegenhein, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of proliferative diseases. His innovative approach has led to the development of a unique dosage regimen that enhances the efficacy of specific therapeutic compounds.
Latest Patents
Schnell holds a patent for a "Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor." This invention relates to methods of treating or preventing a proliferative disease in patients by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound. The regimen involves administering the compound for at least two five-consecutive day cycles, with a break of about two to three days between cycles. This innovative approach aims to optimize treatment outcomes for patients in need.
Career Highlights
Christian René Schnell is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other talented professionals in the field, contributing to advancements in medical treatments and therapies.
Collaborations
Some of Schnell's notable coworkers include Emmanuelle Di Tomaso and Marie-Caroline Germa. Their collaborative efforts have further enhanced the research and development of innovative pharmaceutical solutions.
Conclusion
Christian René Schnell's contributions to the field of pharmaceuticals exemplify the impact of innovative thinking in medicine. His patent and work at Novartis AG highlight the importance of developing effective treatment regimens for patients with proliferative diseases.